Hannah L. Tumbrink - Concepedia

Author

Hannah L. Tumbrink

University of Cologne ORCID

Also Known As

H. Tumbrink, Hannah L. Tumbrink, Hannah Lea Tumbrink, Hannah Tumbrink, Tumbrink, Hannah L.

Publications

835

Citations

H-Index

Concepts

All Affiliations

University of Cologne University Hospital Cologne TU Dortmund University German Cancer Research Center Deutschen Konsortium für Translationale Krebsforschung

About

Hannah L. Tumbrink is an author at University of Cologne specializing in drug discovery, drug development, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	231
2	Natural Sciences	2	2	119
3	Health Sciences	1	1	30
4	Biochemistry	1	1	102
5	Biomolecular Engineering	1	1	55

Hannah L. Tumbrink

Publications

728

Citations

H-Index

Page 1

	Year	Citations
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors Jana Fassunke, Fabienne Müller, Marina Keul, Nature Communications	2018	139
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes Christina M. Bebber, Emily Thomas, Jenny Stroh, Nature Communications	2021	137
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site Marcel Günther, Jonas Lategahn, Michael Juchum, Journal of Medicinal Chemistry Drug TargetBoth Hydrophobic RegionsChemical BiologyMutant Egfr InhibitionPharmaceutical Chemistry	2017	102
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer Marcel A. Dammert, Johannes Brägelmann, Rachelle R. Olsen, Nature Communications	2019	83
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor Stefano Tomassi, Jonas Lategahn, Julian Engel, Journal of Medicinal Chemistry Drug TargetPharmacotherapyDermatologyTumor BiologyMedicinal Chemistry	2017	55
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S Jonas Lategahn, Marina Keul, Philip Klövekorn, Chemical Science	2019	48
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor Julian Engel, Steven P. Smith, Jonas Lategahn, Journal of Medicinal Chemistry Drug TargetMolecular BiologyDrug ResistanceMutant-selective PyrazolopyrimidinesAnti-cancer Agent	2017	30
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors Richard Riedel, Jana Fassunke, Hannah L. Tumbrink, European Journal of Cancer MedicineMechanism Of ActionPharmacotherapyMet InhibitionDrug Development	2022	27
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer Diana Schaufler, David Ast, Hannah L. Tumbrink, npj Precision Oncology	2021	25
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors Jonas Lategahn, Hannah L. Tumbrink, Carsten Schultz‐Fademrecht, Journal of Medicinal Chemistry	2022	23

Page 1